Reports hepatotoxicity prevalence in patients receiving CAR T-cell therapy, suggesting survival remains unaffected.
In this real-world cohort of 231 patients receiving chimeric antigen receptor (CAR) T-cell therapy, hepatotoxicity occurred in 58% of patients, predominantly as transient transaminase elevations, and was not associated with impaired 12-month overall survival (adjusted hazard ratio [HR] 1.18, 95% confidence interval [CI] 0.71-1.94).
No takes yet. Share an insight, caveat, or question.
Hollnberger et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: